Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy.

IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-10-25 DOI:10.1097/CRD.0000000000000620
Jay Patel, Andy Wang, Srihari S Naidu, William H Frishman, Wilbert S Aronow
{"title":"Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy.","authors":"Jay Patel, Andy Wang, Srihari S Naidu, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000620","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in a significant majority. The medical management of obstructive hypertrophic cardiomyopathy has evolved over the decades as our understanding has grown. Traditionally, the mainstay in management has included the use of various negative inotropic agents. In contrast, the cardiac myosin inhibitors, aficamten and mavacamten, are novel therapies targeting cardiac contractility at the sarcomere level that have demonstrated improvement in clinical outcomes for patients, and mavacamten (Bristol Myers Squibb, Inc.) has now been approved by the Food and Drug Administration for the treatment of symptomatic obstructive HCM. Aficamten (Cytokinetics, Inc.) is the second in class cardiac myosin inhibitor that is currently being evaluated in ongoing phase III clinical trials, and is the subject of this review.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"365-368"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology in Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CRD.0000000000000620","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in a significant majority. The medical management of obstructive hypertrophic cardiomyopathy has evolved over the decades as our understanding has grown. Traditionally, the mainstay in management has included the use of various negative inotropic agents. In contrast, the cardiac myosin inhibitors, aficamten and mavacamten, are novel therapies targeting cardiac contractility at the sarcomere level that have demonstrated improvement in clinical outcomes for patients, and mavacamten (Bristol Myers Squibb, Inc.) has now been approved by the Food and Drug Administration for the treatment of symptomatic obstructive HCM. Aficamten (Cytokinetics, Inc.) is the second in class cardiac myosin inhibitor that is currently being evaluated in ongoing phase III clinical trials, and is the subject of this review.

Aficasten——一种治疗肥厚型心肌病的二级心肌肌球蛋白抑制剂。
肥厚型心肌病是一种被低估的疾病,其遗传成分导致左心室异常且往往不对称增厚,此外还会导致顺应性下降和心肌进行性纤维化。随着时间的推移,它进一步引起了与动态左心室流出道梗阻相关的重大并发症,其中绝大多数都是如此。几十年来,随着我们对梗阻性肥厚型心肌病的理解不断加深,其医疗管理也在不断发展。传统上,管理的支柱包括使用各种负性变力剂。相比之下,心肌肌球蛋白抑制剂阿法康腾和马瓦康腾是针对肌节水平心肌收缩性的新型疗法,已证明其改善了患者的临床结果,马瓦康坦(Bristol Myers Squibb,股份有限公司)现已获美国食品药品监督管理局批准用于治疗症状性阻塞性HCM。Aficamten(细胞动力学,股份有限公司)是目前正在进行的III期临床试验中评估的第二类心肌肌球蛋白抑制剂,也是本综述的主题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiology in Review
Cardiology in Review CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
0.00%
发文量
76
审稿时长
>12 weeks
期刊介绍: The mission of Cardiology in Review is to publish reviews on topics of current interest in cardiology that will foster increased understanding of the pathogenesis, diagnosis, clinical course, prevention, and treatment of cardiovascular disorders. Articles of the highest quality are written by authorities in the field and published promptly in a readable format with visual appeal
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信